Zydus Lifesciences Ltd. share price target

trial of the vaccine on 28,000 volunteers, including 1400 subjects in the age group of 12-17 age group. With favorable and acceptable safety profile, the approval was unique as it allows ZyCoV-D to be administered (first time in India) with adolescent age group (12-17 yrs) along with adult population (18 yrs and above). CDH also applied for 2-dose vaccine which may take another 1-2 months for expert group of DCGI to evaluate its efficacy profile data. Thermo-stability (2-8degree temp. for storage) of the vaccine helps in easing storage and transportation costs. Stock filling of the vaccine and commercial...

Cadila Healthcare is India's leading vertically integrated pharmaceutical company. With its presence across the value chain, it manufactures finished dosage forms, active pharmaceutical ingredients, animal healthcare...

We maintain our earnings estimates for FY23E and decrease FY22E following 12% lower estimates on US generics in the quarter, as all Indian peers currently witnessed headwinds due to strong competition and price erosion....

It has a global presence and sells its products in the US, India, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa Cadila is the fourth largest pharma company in India with 14 brands among...

Cadila Healthcare is India's leading vertically integrated pharmaceutical company. With its presence across the value chain, it manufactures finished dosage forms, active pharmaceutical ingredients, animal healthcare...

Q4 revenues were in-line with I-direct estimates whereas profitability was higher due to lower-than-expected other expenditure and DTA related adjustments. On the US front, Cadila plans to venture into complex injectables, which is likely to provide meaningful traction from FY23-24 onwards. The wellness segment performance hinges upon Cadila's marketing & distribution prowess besides effective product positioning. India formulations business, after recent restructuring, is likely to stabilise. The company has significantly improved net debt position in FY21 (nearly...

We revise upgrade our earnings estimate by 22% in FY23E while marginally decreased by 2.4% in FY22E as we increase estimates of Consumer healthcare, India formulations (with 40+ launches) and EU sales while removing animal healthcare sales from 2HFY22 due to sale of business. The 4QFY21 sales were in-line, while earnings beat our estimates with...

CDH delivered in line 4QFY21 earnings. Healthy traction in the Domestic Formulation (DF) and Consumer Wellness has offset the impact of weak US sales and improved EBITDA margin. It is well-placed to benefit from preventive as well as treatment drugs for COVID-19, in addition to improving performance in its core DF portfolio. The innovative pipeline is also progressing well in clinical studies. We maintain our FY22E/FY23E EPS estimate. We continue to value CDH at 25x 12-month forward earnings to arrive at our TP of INR740. We remain...

IPM is struggling for growth above 10% even after MoM abating COVID concerns and with MRs, physician activities almost reaching pre-COVID level. We believe key reasons for growth below par are (i) subdued new prescription (Rx) leading to volume de-growth (ii) digital marketing yield going south and (iii) sustained lower demand of acute products. Cardiac and anti-diabetic growth takes a breather in Jan-21 at 8.8% and 5.3% after reporting double digit growth in most months during lockdown. While amongst top therapies Gastro and VMN reported double digit growth of 14%...